Market Place
Sourcing Support
ABVC BioPharma Reports Q3 2024 Financial Results & Milestones
14 Nov 2024 //
GLOBENEWSWIRE
ABVC BioPharma Receives $50K In Incremental Licensing Fees
22 Oct 2024 //
GLOBENEWSWIRE
ABVC BioPharma Reports Strong Q2 2024 Financials And Strategic Wins
15 Aug 2024 //
GLOBENEWSWIRE
ABVC BioPharma`s CEO Discusses New Drug Development and AI Integration
18 Jul 2024 //
ACCESSWIRE
ABVC BioPharma Executes Licensing Deal for NSCLC Treatment
17 Apr 2024 //
GLOBENEWSWIRE
Skye Bioscience uplists; OncoX`s licensing deal with ABVC BioPharma
10 Apr 2024 //
ENDPTS
ABVC Bio Executes Global Licensing Term Sheet for Oncology/Hematology Products
10 Apr 2024 //
GLOBENEWSWIRE
ABVC Entered into a Global Licensing of Vitargus with Licensing Income of $33.5M
26 Mar 2024 //
GLOBENEWSWIRE
AiBtl BioPharma Completes $7.6M Land Deal: Exchanging Stock for Real Estate
21 Mar 2024 //
GLOBENEWSWIRE
ABVC BioPharma CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
19 Mar 2024 //
GLOBENEWSWIRE
ABVC BioPharma Reports Annual 2023 Financials
14 Mar 2024 //
GLOBENEWSWIRE
ABVC`s New Horizon for Oncology and Hematology Aims at Hundred Billion Dollars
27 Feb 2024 //
GLOBENEWSWIRE
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M
15 Feb 2024 //
GLOBENEWSWIRE
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for MDD
12 Feb 2024 //
GLOBENEWSWIRE
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks
08 Feb 2024 //
GLOBENEWSWIRE
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma
03 Jan 2024 //
GLOBENEWSWIRE
ABVC Announces Completion of Treatment for Analysis on ADHD Ph IIb Study
07 Dec 2023 //
GLOBENEWSWIRE
ABVC Bio Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center
05 Dec 2023 //
GLOBENEWSWIRE
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
21 Nov 2023 //
GLOBENEWSWIRE
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M
16 Nov 2023 //
GLOBENEWSWIRE
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
15 Nov 2023 //
GLOBENEWSWIRE
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs
26 Oct 2023 //
GLOBENEWSWIRE
ABVC Announces Completion of Subject Recruitment for Analysis on ADHD Study
17 Oct 2023 //
GLOBENEWSWIRE
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of MDD
09 Oct 2023 //
GLOBENEWSWIRE
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
23 Aug 2023 //
GLOBENEWSWIRE
ABVC Bio to break ground in China, advances 20% stake in Zhonghui real estate
18 Aug 2023 //
ENDPTS
ABVC Executes Cooperation Agreement for Strategic Investments
17 Aug 2023 //
GLOBENEWSWIRE
ABVC BioPharma Regains Compliance With Nasdaq`s Minimum Bid Price Requirement
10 Aug 2023 //
GLOBENEWSWIRE
ABVC Corporate Update and CEO`s Letter to Shareholders
07 Aug 2023 //
GLOBENEWSWIRE
ABVC Announces Approval of the Plan for GMP Production Facilities of Vitargus
03 Aug 2023 //
GLOBENEWSWIRE
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M
01 Aug 2023 //
GLOBENEWSWIRE
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
31 Jul 2023 //
GLOBENEWSWIRE
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
27 Jul 2023 //
GLOBENEWSWIRE
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
26 Jul 2023 //
GLOBENEWSWIRE
ABVC BioPharma Announces Reverse Stock Split
24 Jul 2023 //
GLOBENEWSWIRE
The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency
06 Jul 2023 //
GLOBENEWSWIRE
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
26 Jun 2023 //
GLOBENEWSWIRE
ABVC BioPharma Subsidiary BioKey Projects $1.0 M From Dietary Supplement
20 Jun 2023 //
GLOBENEWSWIRE
ABVC Bio ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
12 Jun 2023 //
GLOBENEWSWIRE
ABVC BioPharma Announces Collaboration With MerDury BioPharma
06 Jun 2023 //
GLOBENEWSWIRE
ABVC BioPharma Vitargus Phase II Study Received Ethical Approval
22 May 2023 //
GLOBENEWSWIRE
ABVC BioPharma Receives US Patent Certificate of PDC-1421
04 May 2023 //
GLOBENEWSWIRE
ABVC BioPharma Announces Completion of Ph II Part2 Study Site Initiation UCSF
26 Apr 2023 //
GLOBENEWSWIRE
ABVC Bio Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted
10 Apr 2023 //
GLOBENEWSWIRE
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit
06 Apr 2023 //
GLOBENEWSWIRE
ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results
31 Mar 2023 //
GLOBENEWSWIRE
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit
20 Mar 2023 //
PR NEWSWIRE
ABVC Receives Registration Approval for Maitake Mushroom Dietary Supplement
14 Mar 2023 //
PR NEWSWIRE
ABVC BioPharma Provides 2023 Pipeline Update
28 Feb 2023 //
GLOBENEWSWIRE
ABVC Receives $3.175M Investment From The Lind Partners to Continue Trials
23 Feb 2023 //
GLOBENEWSWIRE
ABVC Receives Australian TGA Approval to Initiate Phase II Study of Vitargus
21 Feb 2023 //
GLOBENEWSWIRE
ABVC BioPharma ABV-1505 ADHD Ph IIa Results Presented at 2023 APSARD Conference
19 Jan 2023 //
GLOBENEWSWIRE
FDA Approves IND Submission Allowing ABVC BioPharma
05 Jan 2023 //
GLOBENEWSWIRE
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study
17 Nov 2022 //
GLOBENEWSWIRE
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
14 Nov 2022 //
GLOBENEWSWIRE
ABVC Receives Notice of Allowance from US Patent & Trademark Office for ABV-1504
07 Nov 2022 //
GLOBENEWSWIRE
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC
05 Oct 2022 //
GLOBENEWSWIRE
ABVC BioPharma Provides ADHD PhII Part2 Clinical Study Update and Announces UCSF
23 Sep 2022 //
GLOBENEWSWIRE
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
09 Sep 2022 //
GLOBENEWSWIRE
ABVC Provides Oncology Pipeline Updates
22 Aug 2022 //
GLOBENEWSWIRE
